Literature DB >> 22352868

Structure-activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres.

Kazuya Kobayashi1, Shinya Oishi, Ryoko Hayashi, Kenji Tomita, Tatsuhiko Kubo, Noriko Tanahara, Hiroaki Ohno, Yasushi Yoshikawa, Toshio Furuya, Masaru Hoshino, Nobutaka Fujii.   

Abstract

A structure-activity relationship study on a highly potent CXC chemokine receptor type 4 (CXCR4) antagonist, FC131 [cyclo(-d-Tyr(1)-Arg(2)-Arg(3)-Nal(4)-Gly(5)-)], was carried out using a series of alkene isosteres of the d-Tyr(1)-l/d-Arg(2) dipeptide to investigate the binding mode of FC131 and its derivatives with CXCR4. The structure-activity relationships of isostere-containing FC131 analogues were similar to those of the parent FC131 and its derivatives, suggesting that a trans-conformer of the d-Tyr(1)-Arg(2) peptide bond is the dominant contributor to the bioactive conformations of FC131. Although NMR analysis demonstrated that the two conformations of the peptidomimetic containing the d-Tyr(1)-d-Arg(2) isostere are possible, binding-mode prediction indicated that the orientations of the alkene motif within d-Tyr(1)-MeArg(2) peptidomimetics depend on the chirality of Arg(2) and the β-methyl group of the isostere unit, which makes the dominant contribution for binding to the receptor. The most potent FC122 [cyclo(-d-Tyr(1)-d-MeArg(2)-Arg(3)-Nal(4)-Gly(5)-)] bound with CXCR4 by a binding mode different from that of FC131.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352868     DOI: 10.1021/jm2016914

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

4.  Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.

Authors:  Takuya Kobayakawa; Yudai Matsuzaki; Kentaro Hozumi; Wataru Nomura; Motoyoshi Nomizu; Hirokazu Tamamura
Journal:  ACS Med Chem Lett       Date:  2017-12-27       Impact factor: 4.345

Review 5.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting.

Authors:  Chao Xu; Hong Zhao; Haitao Chen; Qinghua Yao
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

6.  Polar functional group-containing glycolipid CD1d ligands modulate cytokine-biasing responses and prevent experimental colitis.

Authors:  Shinsuke Inuki; Natsumi Hirata; Emi Kashiwabara; Junichiro Kishi; Toshihiko Aiba; Toshiaki Teratani; Wataru Nakamura; Yoshimi Kojima; Toru Maruyama; Takanori Kanai; Yukari Fujimoto
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.